Lumicell Headquarters Expands Into New Boston-Area Office Space

New location offers more space for future expansions and is designed
to inspire innovation of Lumicell technology through further employee

NEWTON, Mass.–(BUSINESS WIRE)–Lumicell, Inc., an innovation leader in molecular imaging within
healthcare focused in cancer, perfusion, wound care and infection, has
expanded into a new headquarters location in Newton, Mass., just outside
of Boston.

The new office space at One Newton Place, 275 Washington St., is over
20K sq. ft. in size and has been completely renovated to meet Lumicell’s
needs for a contemporary workspace that is reflective of the
collaboration and creativity required to develop their molecular imaging
technology. This location is in an ideal area for Lumicell. Not only is
it close to downtown Boston and Cambridge, where much of its research
and development workforce hails from, but it also offers a more
commercial setting for the business, with room for future expansions.

“This space represents a huge growth milestone for Lumicell. As we grow
into more Oncology indications and future healthcare projects, we now
have an office environment that supports the expansion of our platform,”
said Kelly Londy, CEO of Lumicell. “Every decision for this space was
focused on efficiency, collaboration and technology that pushes
engineering solutions to positively impact patients and clinicians. In
fact, we have room for clinical trainings and education events with
medical teams from hospitals and local universities who work
collaboratively with our team.”

The company’s lead product, the Lumicell System, is in late-stage
development for breast cancer surgery. It features an investigational
optical agent and a handheld device that enable cancer surgeons to see
and remove cancer cells in real-time during operations. The Lumicell
System was designed and developed by MIT engineers in partnership with
leading breast cancer surgeons to fit seamlessly within the existing
surgical workflow.

About Lumicell, Inc.
Lumicell is a technology leader in the
field of image-guided cancer surgery. The company is developing a novel
system that enables real-time detection of tumor tissue in patients so
that no cancer cells are left behind during surgery. The company’s
Lumicell System has unprecedented ability to see and remove cancer cells
remaining in the surgical cavity – beyond the margin of the specimen –
and has the potential to significantly improve surgical outcomes and
reduce healthcare costs by eliminating the need for repeat surgeries.
Lumicell is investigating the Lumicell System in patients undergoing
surgery for breast cancer, ovarian cancer, prostate cancer, brain
cancer, colorectal, esophageal and pancreatic cancers. Additional future
indications are planned to include perfusion, wound care and infection,
and surgeries for lung, and liver cancers. For more information, please


Media contact: Ali Buckneberg
number: 612-334-5960

error: Content is protected !!